Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis
Conditions
Interventions
Efzofitimod 1.0 mg/kg or Placebo
Efzofitimod 3.0 mg/kg or Placebo
+1 more
Locations
15
United States
University of Alabama
Birmingham, Alabama, United States
aTyr Investigative Site
Northridge, California, United States
National Jewish Health
Denver, Colorado, United States
aTyr Investigative Site
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Start Date
January 29, 2019
Primary Completion Date
June 29, 2021
Completion Date
June 29, 2021
Last Updated
July 18, 2023
NCT06169397
NCT04064242
NCT06113991
NCT03599414
NCT04173689
NCT01587001
Lead Sponsor
aTyr Pharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions